Perception & Acceptability of a Cervical Cancer Prevention Prebiotic Device

PreBioGyn will be compared to market leading vaginal pH buffering gels using established forearm test methods associated with vaginal lubricity sensation in 42 women. Women will also rate each gel for smell and appearance using established methods. The PreBioGyn gel enclosure and intravaginal applicator design will be evaluated for: look and feel, ability to prepare for dosing, ability to expulse dose, and likelihood of future use by subjects. Open-ended feedback on the gel and applicator will occur to gather contributions for each product.

Study Overview

• Status: Completed
• Conditions: Sensory Perceptual Characteristics; User Acceptability of Gel Delivery System
• Intervention / Treatment: Other: PreBioGyn Gel; Other: Trimosan Gel; Other: RepHresh Gel

Detailed Description

This study is being conducted as a component of a NIH/NCI sponsored Small Business Technology Transfer (STTR) project entitled "Cervical Cancer Prevention Prebiotic Device."

The prebiotic vaginal gel, PreBioGyn, has been developed to optimize vaginal health and reduce the risk of cervical cancer in women. Use of the gel targets a combination of biological risk factors for cervical cancer including restoring and maintaining healthy vaginal microbiota, pH, and mucosal function, thereby preventing disturbed immunity and inflammation caused by dysbiosis and mucosal microtrauma. The purpose of this study is to provide a quantitative perception evaluation of the acceptability of PreBioGyn and its applicator system.

The objectives of this study are to:

1. Perform a quantitative sensory evaluation to determine the topical acceptability of PreBioGyn, as well as receive qualitative feedback on the gel, as compared to competitive products.
2. Obtain quantitative and qualitative feedback regarding acceptability of the PreBioGyn applicator compared to those for existing competitive products.

These Study Objectives do not involve actual intravaginal use of the product. Rather, this activity will involve presentation of the products in a forearm and finger-touch sensory evaluation, and the answering of questions related to this perceptual evaluation.

Study Design:

This is a randomized, single-blind, cross-over study that will include 42 women.

Study Procedures and Methods:

Quantitative sensory evaluation and qualitative feedback to determine the acceptability of the prebiotic vaginal gel (PreBioGyn) as compared to competitive products

Summary:

Quantitative evaluation of PreBioGyn and two competitive vaginal pH buffer-gels will be performed. The four key qualitative parameters to be evaluated are slipperiness, tackiness, appearance, and smell. These parameters are key functional outcomes for the final PreBioGyn formula. Qualitative feedback and likelihood of use for each gel will also be collected and scored.

1. Quantitative Assessment of Slipperiness and Tackiness ("lubricity").

   Quantitative perceptual lubricity (slipperiness and tackiness) will be determined using a standardized methodology wherein participants discriminate differences between the PreBioGyn and two competitive products, versus positive and negative anchor products. Products are evaluated on the skin (forearm area) ex vivo.

   Participants will each receive the positive and negative anchors, then the three gel products, on three different 4-cm circular forearm sites. The order of the gels, and the circle to which it was applied, will be determined randomly based on a computer-generated randomization table. Each treatment is replicated twice. Participants will be blinded to the specific products used.

   Fingers and circles will be wiped with a low-residue baby-wipe and paper towel. The investigator dispenses 0.2 ml of the sample into the center of the circle previously drawn on the forearm. The sample is rubbed in a circle using the index finger at a rate of 2 revolutions per second for 15 seconds and followed with another 45 seconds (60 second time point). A metronome is set at 120 bpm and played to standardize the manipulation rate.

   At time points 15 and 60 seconds, slipperiness is evaluated using a visual analog scale (VAS). The two ends of the visual analog scale are anchored by the phrases "not slippery" and "very slippery." The participant is asked to make a mark on the VAS at the point of their slipperiness assessment between the two anchors. Prior to study gel measurements, participants will perform evaluations on two products representing the negative anchor "not slippery" (lanolin) and positive anchor "very slippery" (Gun Oil™ lubricant).

   At the 60-second time point, and after the slipperiness score is recorded, subjects will assess tackiness by tapping their finger up and down for 5 seconds on the skin in the circle just used to assess slipperiness.

   Tackiness is evaluated using the visual analog scale. The two ends of the visual analog scale are anchored by the phrases "Not tacky or sticky" and "very tacky or sticky." The focus group participant is asked to make a mark on the VAS at the point of their tackiness assessment between the two anchors. Prior to study gel measurements, participants will perform evaluations on two products representing the anchors of "very tacky" (lanolin) and "not tacky" (Gun Oil® lubricant). The degree of slipperiness and tackiness is determined by measuring the distance of the participants mark on the visual analog scale from the left baseline.

2. Qualitative Assessment of Appearance and Smell and Overall Perception.

   Study participants will be asked to rate the appearance and smell of the PreBioGyn and competitive products following the end of the quantitative assessment period. The traditional nine-point hedonic scale will be used to assess the degree of liking or disliking of each gel's smell and appearance. The reliability, validity and discriminative ability of the scale has been proven in food, cosmetic, and personal care product acceptance tests.

   Two milliliters (2 ml) of each lubricant will be dispensed from a prefilled syringe onto a small clear plastic petri dish. The order of the gel will be determined randomly based on a computer-generated randomization table. Each treatment is replicated twice. Participants will be blinded to the product identity. Subjects will be asked to observe the gels under good lighting, smell the gels from a distance of approximately 2-5 cm from the end of their nose, and then rate each gel on the Hedonic scale. Finally, open-ended feedback on the gels, including likelihood of use as a proposed product to decrease cervical cancer risk, will occur using the "I Like, I Wish, What If" method to gather participant contributions.

3. Quantitative and Qualitative Feedback Regarding Acceptability of the PreBioGyn Applicator Compared to Competitive Products.

Women will rank the PreBioGyn applicator versus that of competitive products in a 9-point Hedonic scale for acceptability of the applicator look and feel; the usability for preparing the applicator for dosing, and the usability to expel the gel (table-top). Finally, the overall reaction to the concept of inserting each applicator vaginally will be rated, as well as a 5-point Likert-scale rating of likelihood of future use of each product to reduce cervical cancer risk. Finally, open-ended feedback on the applicators will occur using the "I Like, I Wish, What If" method to gather participant contributions.

• Study Type: Interventional
• Enrollment (Actual): 42
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Puerto Rico
  • San Juan, Puerto Rico, 00936
    • University of Puerto Rico Medical Sciences
• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Brigham and Women's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female
• hrHPV positive
• 30 years of age or older
• Have not received the HPV vaccine
• Not pregnant or nursing
• Medicaid eligible

Exclusion Criteria:

• history of skin irritation and/or allergic skin reactions

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PreBioGyn Gel; Topical administration to forearm	Other: PreBioGyn Gel; Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.
Active Comparator: Trimosan Gel; Topical administration to forearm	Other: Trimosan Gel; Carbomer-based gel
Active Comparator: RepHresh Gel; Topical administration to forearm	Other: RepHresh Gel; Carbomer-based gel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Sensory perceptual characteristics of gels based on forearm testing	1 hour
User acceptability of gel delivery system	1 hour

Collaborators and Investigators

• Sponsor: Glyciome, LLC
• Collaborators: Brigham and Women's Hospital; University of Puerto Rico
• Investigators: Principal Investigator: Joanna Ellington, PhD, Glyciome, LLC

Study record dates

Study Major Dates

• Study Start (Actual): February 24, 2022
• Primary Completion (Actual): November 28, 2022
• Study Completion (Actual): November 28, 2022

Study Registration Dates

• First Submitted: April 8, 2021
• First Submitted That Met QC Criteria: April 8, 2021
• First Posted (Actual): April 12, 2021

Study Record Updates

• Last Update Posted (Estimate): December 6, 2022
• Last Update Submitted That Met QC Criteria: December 4, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Uterine Cervical Neoplasms
• Other Study ID Numbers: R41CA254543 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No